The PREVEND IT. Source:
Brouwers FP, Asselbergs FW, Hillege HL, et al. Long-term effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria: ten years of follow-up of Prevention of Renal and Vascular End-stage Disease Intervention Trial (PREVEND IT). Am Heart J. 2011;161(6):1171–1178.
This study understands the effect of treatment that is targeted at lowering urinary albumin excretion (UAE). Extended follow-up data of over 10 years has also been accumulated, which helped to investigate the long-term effects of fosinopril and pravastatin on cardiovascular (CV) outcomes.
• Number of patients: 864 participants and 839 survivors after 4 years.
• Primary endpoint of every survivor was determined by the combined incidence of CV mortality and hospitalization for CV morbidity.
• Mean total extended follow-up in the PREVEND IT was 9.5 years (range: 9.4–10.7 years).
• No reduction in the primary endpoint compared to placebo was observed in fosinopril group after 4 years of treatment (hazard ratio [HR]: 0.87, 95% CI: 0.61–1.24 [p=0.42]).
• Total event rate of 29.5% seen in subjects with a baseline UAE in the upper quintile (>50 mg/24 h) after 9.5 years. They were also at high risk for developing CV diseases (HR: 2.03, 95% CI: 1.38–2.97 [p≤0.01]).
• Risk reduction of 45% observed in fosinopril treatment group compared to placebo (95% CI: 6–75% [p=0.04]).
• No overall risk reduction in primary endpoint observed in subjects who were assigned to pravastatin (p=0.99).
There exists a positive correlation between elevated UAE and CV mortality and morbidity; the CV risk doubles if the UAE exceeds >50 mg/day.